Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Core Viewpoint - Clearmind Medicine Inc. has received approval to continue its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic neuroplastogen aimed at treating Alcohol Use Disorder (AUD), based on positive safety results from the second cohort of participants [1][4]. Group 1: Clinical Trial Progress - The independent Data and Safety Monitoring Board (DSMB) completed a second interim review and recommended the continuation of the trial due to encouraging safety data from the second cohort [1][2]. - The second cohort involved six participants and demonstrated a favorable safety profile, reinforcing the results from the first cohort [2][3]. - The trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, conducted at leading medical centers [4]. Group 2: Dosage and Administration - In the second cohort, participants received a dose that was double that of the first cohort, with no serious adverse events reported, supporting the trial's progression to the third cohort with an 80 mg dose [3][4]. - The successful completion of treatment in the second cohort occurred shortly after DSMB clearance, indicating confidence in CMND-100's safety profile [4]. Group 3: Company Overview - Clearmind Medicine Inc. is focused on developing novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [5]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [6].